anemia

(redirected from Anemias)
Also found in: Dictionary, Medical, Encyclopedia.
Related to Anemias: aplastic anemia, Hemolytic anemias
Graphic Thesaurus  🔍
Display ON
Animation ON
Legend
Synonym
Antonym
Related
  • noun

Synonyms for anemia

References in periodicals archive ?
To name our case, a literature search was made and it was found that the cases with similar findings were defined as aplastic anemia (1,2).
The patient in your report has been defined as severe pancytopenic but the criteria used for severe aplastic anemia is the presence of two out of following three; neutrophil count less than 200 cells/microliter, platelet count less than 20.
Compare the prevalence of anemia in a variety of subgroups in persons over age 65.
Discuss the physical, cognitive, and economic impact of anemia in the elderly.
Anemia gradually develops several months after starting a diet deficient in vitamin A.
8) Riboflavin deficiency can cause a normochromic, normocytic anemia and reticulocytopenia that responds to supplementation.
Three weeks later, stem cells from that blood were transplanted into 6-year-old Molly, who suffered from Fanconi anemia.
The first couple that attempted the procedure lost a son to Fanconi anemia after nine futile efforts to bear a stem cell donor for him, Wagner says.
To capitalize on the link between the two findings, Perrine and her colleagues gave three sickle cell anemia patients and three beta-thalassemia patients daily infusions of a butyrate solution for either two or three weeks.
and his colleagues report that a combination of the anticancer drug hydroxyurea and the red blood cell growth factor erythropoietin increased the fetal hemoglobin concentrations in four patients with either sickle cell anemia or beta-thalassemia.
As a result of this agreement, we can focus our resources on completing the development and commercializing oral anemia therapy in North America where the majority of the anemia markets are not yet penetrated," said Mr.
FG-2216 and FG-4592 are investigational oral anemia therapies designed to restore balance to the body's natural process of erythropoiesis (production of oxygen-carrying red blood cells) through mechanisms including: natural EPO production, suppression of the effects of inflammation, down-regulation of the iron sequestration hormone hepcidin, and an up-regulation of other iron genes, ensuring efficient mobilization and utilization of the body's own iron stores.
We are encouraged by these preliminary data that suggest the magnitude and rate of hemoglobin increases observed in patients treated with FG-2216 are likely to provide clinical benefit in treating anemia associated with CKD.
FibroGen is now conducting clinical studies evaluating various dosing regimens of FG-2216 in patients with anemia of chronic kidney disease.